INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action...

The average of price targets set by Wall Street analysts indicates a potential upside of 297% in ARS Pharmaceuticals, Inc. (SPRY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

SPRY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ARS Pharmaceuticals Securities Lawsuit - Contact Levi & Korsinsky SPRY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ARS Pharmaceuticals Securities Lawsuit - Contact Levi & Korsinsky...

SPRY Shareholder Alert: ARS Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm SPRY Shareholder Alert: ARS Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm PR Newswire NEW YORK, Aug. 18, 2026 NEW...

Robbins LLP Urges SPRY Stockholders Who Lost Money Investing in ARS Pharmaceuticals Inc. to Contact the Firm for Information About Leading the Class Action Lawsuit Robbins LLP Urges SPRY Stockholders Who Lost Money Investing in ARS Pharmaceuticals Inc. to Contact the Firm for Information About...

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK, Aug. 16, 2026 NEW YORK, Aug. 16, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor...

Stocks Set To Post Fresh All Time High As Tech Euphoria Returns Futures are fractionally higher, as they have been much of this supercharged week which pushed stocks to new all tim ehighs,?amid quiet news flow this morning. As of 8:00am ET, S&P futures are up 0.1%?after the index...

ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -14.55% and +5.54%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

SPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026 SPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026 PR Newswire NEW YORK, Aug...